Antivenom development in Australia

Frank Madaras, Peter J. Mirtschin, Tim Kuchel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Brown snakes, Pseudonaja genus, cause more bites and deaths to animals and humans in Australia than any other terrestrial snake genus. Some aspects of treatment of brown snakebites with antivenom remain poorly managed due to the apparent inability of the antivenom to counter the prothrombin activator in the venom. We present evidence of a new novel antivenom (Antiven Pty Ltd Brown snake antivenom (ABSAV)), which shows high efficacy in reversing the hemostatic abnormality caused by brown snake envenomation. It is also more, efficient at reversing overall toxicity. In clotting tests, it is substantially more potent than Commonwealth Serum Laboratories Ltd (CSL) Brown snake antivenom and is twice as effective in reversing overall toxicity than CSL Brown snake antivenom. Antiven Pty. Ltd. Brown snake antivenom is currently being assessed by the National Registration Authority (veterinary regulative body in Australia).

LanguageEnglish
Pages79-94
Number of pages16
JournalJournal of Toxicology - Toxin Reviews
Volume24
Issue number1
DOIs
Publication statusPublished - 17 May 2005

Keywords

  • Antivenom
  • Elapid
  • IgG
  • IgY
  • Pseudonaja

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this